Fayerweather Charles lowered its stake in Danaher Co. (NYSE:DHR) by 3.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 18,388 shares of the conglomerate’s stock after selling 596 shares during the period. Danaher makes up approximately 2.5% of Fayerweather Charles’ portfolio, making the stock its 17th biggest holding. Fayerweather Charles’ holdings in Danaher were worth $1,706,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Notis McConarty Edward grew its stake in shares of Danaher by 10.2% in the fourth quarter. Notis McConarty Edward now owns 28,725 shares of the conglomerate’s stock worth $2,666,000 after purchasing an additional 2,650 shares during the last quarter. Public Employees Retirement Association of Colorado grew its stake in shares of Danaher by 13.0% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 600,792 shares of the conglomerate’s stock worth $55,766,000 after purchasing an additional 69,322 shares during the last quarter. Puzo Michael J grew its stake in shares of Danaher by 32.6% in the fourth quarter. Puzo Michael J now owns 55,456 shares of the conglomerate’s stock worth $5,147,000 after purchasing an additional 13,627 shares during the last quarter. Kidder Stephen W grew its stake in shares of Danaher by 4.4% in the fourth quarter. Kidder Stephen W now owns 58,405 shares of the conglomerate’s stock worth $5,421,000 after purchasing an additional 2,484 shares during the last quarter. Finally, Dempze Nancy E grew its stake in shares of Danaher by 17.9% in the fourth quarter. Dempze Nancy E now owns 28,301 shares of the conglomerate’s stock worth $2,626,000 after purchasing an additional 4,305 shares during the last quarter. Hedge funds and other institutional investors own 76.19% of the company’s stock.

Shares of Danaher Co. (NYSE DHR) opened at $96.70 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $67,270.00, a P/E ratio of 27.63, a price-to-earnings-growth ratio of 2.20 and a beta of 1.04. Danaher Co. has a 12-month low of $78.97 and a 12-month high of $104.82.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.03. The business had revenue of $5.09 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The business’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.05 EPS. equities research analysts anticipate that Danaher Co. will post 4.37 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 26th. Shareholders of record on Friday, December 29th were given a dividend of $0.14 per share. The ex-dividend date was Thursday, December 28th. This represents a $0.56 annualized dividend and a yield of 0.58%. Danaher’s payout ratio is 16.00%.

In other news, CFO Daniel L. Comas sold 62,989 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $101.96, for a total value of $6,422,358.44. Following the sale, the chief financial officer now directly owns 227,805 shares of the company’s stock, valued at approximately $23,226,997.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP William K. Daniel sold 131,066 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $102.05, for a total value of $13,375,285.30. Following the completion of the sale, the executive vice president now directly owns 270,523 shares in the company, valued at $27,606,872.15. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 274,913 shares of company stock worth $27,729,293. Insiders own 12.20% of the company’s stock.

DHR has been the topic of several recent analyst reports. Robert W. Baird reissued a “buy” rating and issued a $99.00 target price on shares of Danaher in a research note on Friday, December 15th. Citigroup raised their target price on Danaher to $107.00 and gave the stock a “buy” rating in a research note on Friday, December 15th. Cowen reissued a “buy” rating and issued a $110.00 target price on shares of Danaher in a research note on Tuesday, January 30th. UBS Group initiated coverage on Danaher in a research note on Monday, January 22nd. They issued a “buy” rating and a $99.97 target price on the stock. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $110.00 target price on shares of Danaher in a research note on Friday, January 19th. One analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Danaher currently has a consensus rating of “Buy” and an average price target of $100.13.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/fayerweather-charles-has-1-71-million-stake-in-danaher-co-dhr/1848753.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.